Oncolytic vaccinia virus mutants and using same for cancer treatment
US-2019183947-A1 · Jun 20, 2019 · US
Pharmaceutical compositions comprising caffeic acid chelates
US11458203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11458203-B2 |
| Application number | US-201816612222-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 8, 2018 |
| Priority date | May 8, 2017 |
| Publication date | Oct 4, 2022 |
| Grant date | Oct 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to pharmaceutical compositions comprising caffeic acid chelates, kits, and methods for using such compounds and pharmaceutical compositions.
First claim
Opening claim text (preview).
What is claimed: 1. A method of treating a subject infected with Ebola virus, the method comprising administering to the subject a complex of a compound, or a pharmaceutical composition comprising the complex in an amount to treat infection by the Ebola simplex virus in the subject, wherein the compound is and the complex comprises Fe+ 3 . 2. A method of treating a subject infected with herpes simplex virus, the method comprising administering to the subject a complex of a compound, or a pharmaceutical composition comprising a complex of the compound and a pharmaceutically acceptable carrier in an amount to treat infection by the herpes simplex virus in the subject, wherein the compound is: wherein the complex comprises Fe + 3 .
Assignees
Inventors
Classifications
having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} · CPC title
- A61K47/547Primary
Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent · CPC title
- A61K9/0019Primary
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11458203B2 cover?
- The present disclosure relates to pharmaceutical compositions comprising caffeic acid chelates, kits, and methods for using such compounds and pharmaceutical compositions.
- Who is the assignee on this patent?
- Arizona Board Of Regents On Behald Of Arizona State Univ, Univ Arizona State
- What technology area does this patent fall under?
- Primary CPC classification A61K47/547. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).